Search

Your search keyword '"Harter, Agnès"' showing total 10 results
Start Over Author "Harter, Agnès"
10 results on '"Harter, Agnès"'

2. Molecular evolution of omicron variant in immunocompromised individuals with chronic SARS-CoV-2 infection

Author

Vellas, Camille, primary, Latour, Justine, additional, Trémeaux, Pauline, additional, Ranger, Noémie, additional, Ferrer, Vénicia, additional, Harter, Agnès, additional, Carcenac, Romain, additional, Boyer, Pauline, additional, Demmou, Sofia, additional, Claraz, Pauline, additional, Kamar, Nassim, additional, and Izopet, Jacques, additional

Published
2023
Full Text
View/download PDF

6. HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment.

Author

Raymond, Stéphanie, Jeanne, Nicolas, Nicot, Florence, Dimeglio, Chloé, Carcenac, Romain, Harter, Agnès, Ranger, Noémie, Martin-Blondel, Guillaume, Delobel, Pierre, and Izopet, Jacques

Subjects
RALTEGRAVIR, REVERSE transcriptase inhibitors, ANTI-HIV agents, ANTIRETROVIRAL agents, INTEGRASE inhibitors, DRUG resistance, HIV, HEPATITIS C virus
Abstract

Objectives: To evaluate the routine use of the Sentosa ultra-deep sequencing (UDS) system for HIV-1 polymerase resistance genotyping in treatment-naïve individuals and to analyse the virological response (VR) to first-line antiretroviral treatment.Methods: HIV drug resistance was determined on 237 consecutive samples from treatment-naïve individuals using the Sentosa UDS platform with two mutation detection thresholds (3% and 20%). VR was defined as a plasma HIV-1 virus load <50 copies/mL after 6 months of treatment.Results: Resistance to at least one antiretroviral drug with a mutation threshold of 3% was identified in 29% and 16% of samples according to ANRS and Stanford algorithms, respectively. The ANRS algorithm also revealed reduced susceptibility to at least one protease inhibitor (PI) in 14.3% of samples, to one reverse transcriptase inhibitor in 12.7%, and to one integrase inhibitor (INSTI) in 5.1%. For a mutation threshold of 20%, resistance was identified in 24% and 13% of samples according to ANRS and Stanford algorithms, respectively. The 6 months VR was 87% and was similar in the 58% of patients given INSTI-based treatment, in the 16% given PI-based treatment and in the 9% given NNRTI-based treatment. Multivariate analysis indicated that the VR was correlated with the baseline HIV virus load and resistance to at least one PI at both 3% and 20% mutation detection thresholds (ANRS algorithm).Conclusions: The Vela UDS platform is appropriate for determining antiretroviral resistance in patients on a first-line antiretroviral treatment. Further studies are needed on the use of UDS for therapeutic management. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes

Author

Nicot, Florence, primary, Dimeglio, Chloé, additional, Migueres, Marion, additional, Jeanne, Nicolas, additional, Latour, Justine, additional, Abravanel, Florence, additional, Ranger, Noémie, additional, Harter, Agnès, additional, Dubois, Martine, additional, Lameiras, Sonia, additional, Baulande, Sylvain, additional, Chapuy-Regaud, Sabine, additional, Kamar, Nassim, additional, Lhomme, Sébastien, additional, and Izopet, Jacques, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results